'valves,' and anatomy of the systemic and pulmonary circulations. By the 19th century, the major layers constituting blood vessels were identified and often described in the analysis of pathological specimens, such as aneurysms.2 However, it has been only during the past 20 years that specific biochemical mechanisms modulating contractile protein interaction in vascular smooth muscle have been described and characterized both in vitro and in living muscle. Even more recently, the endothelium has been identified as an important endocrine modulator of vascular reactivity and growth. Simultaneously, converging disciplines involving molecular and cellular biology, as well as clinical studies of atherosclerosis, have brought to bear both increased attention and research on blood vessels. This increased interest and activity virtually ensure that the next decade of research will more fully explore the integrated function of the cells that compose the blood vessel; it is pathology of the vascular wall that leads to the constellation of problems that constitute ischemic heart disease.
This review focuses on the myogenic component of blood vessels: vascular smooth muscle. Particular emphasis is given to molecular mechanisms that regulate contractile properties of this tissue.
Vascular Myocyte Structure The tone-generating capacity of vascular smooth muscle is dependent on the interaction between the major contractile proteins, actin and myosin. 3 An analogy to the sliding-filament model of striated muscle contraction is made by most investigators of vascular contractility. 4 In this model, the heads of myosin molecules, which are bundled together into thick filaments, undergo a cycle of high-and lowaffinity binding to actin in a reaction driven by ATP hydrolysis. Tension generation occurs as a result of translocation of the heads of myosin, which are bound to actin, from an angle of 900 to 450 with respect to the long axis of actin-and myosin-containing filaments. The direction of force is determined by the polarity of these filaments. Thus, for smooth muscle cells to shorten or develop isometric tension, filaments of opposing polarity must extend from opposite ends of an anchoring structure. In striated muscle, the organization of thick (myosin) and thin (actin) filaments is highly ordered, and banded structures corresponding to various filamentous elements are readily observed under light microscopy. 5 The organization of filaments in smooth muscle is less apparent, and an unambiguous model of the cytoskeleton remains to be elucidated. 6, 7 In smooth muscle, thin filaments comprising actin, tropomyosin, and other proteins are attached to the cell membrane via membrane plaques. These structures contain several proteins including vinculin, metavinculin, a-actinin, and talin.8 Within the cytoplasm, thin filaments insert into fusiform dense bodies,9 which contain a-actinin and other unidentified proteins. 47 Because both actin and myosin are thought to be involved in such processes as cytokinesis and possibly chromosomal translocation during mitosis, it is conceivable that this isoenzyme is involved in modulating these processes by a conserved capacity for interaction with actomyosin.
Caldesmon enhances the binding of myosin subfragments to actin48 as a result of an interaction of the amino terminal portion of the molecule with the S2 portion of myosin rod. 49 Recently, Adam et a150 showed that several pharmacological agonists that induce the latch state in vascular smooth muscle also stimulate phosphorylation of caldesmon. It is possible that phosphorylated caldesmon, acting through actin and tropomyosin, slows crossbridge detachment by altering actomyosin binding or ATPase kinetics. 48 Identification of the specific kinase that phosphorylates caldesmon and elucidation of its regulation will be essential to test the latter hypothesis. However, the actual function of caldesmon is not known.
Contractile Protein Isoforms and
Vascular Contractility A thorough evaluation of the importance of contractile protein isoforms in modulating vascular contractility remains incomplete. However, recent studies have demonstrated the presence of at least two isoforms of myosin heavy chain5' in smooth muscle, two forms of the LC20,5253 and two forms of the LC17.54 DNA-cloning studies have shown that isoforms of the heavy chain55 and the alkali light chain56 arise from alternative RNA splicing of a single gene, whereas LC20 forms are most likely products of separate genes.5253 In addition, vascular smooth muscle contains a unique a-actin that is the product of a gene distinct from those that encode the sarcomeric a-actins of cardiac and skeletal muscle.57
The principal structural difference between myosin heavy chains in vascular smooth muscle resides in an extended 45-amino acid carboxyl terminus of the larger of the two isoforms. Although the functional significance of this is not known, embryological studies in the rat have shown that there is developmental regulation of heavy chain isoform expression; the 200-kDa form is found in fetal vasculature, whereas the 204-kDa form appears during the neonatal period.58 Vasculature of mature animals contains an approximate 1:1 mixture of the myosin heavy-chain isoforms.58 Because it is the carboxyl terminal region of the heavy chain that forms the a-helical rod structure of the myosin molecule, which is prerequisite for filament formation, it is likely that these isoforms possess inherent differences in filamentforming capacity or in regulation of thick filament assembly or disassembly. With regard to the latter, it has recently been shown that the 204-kDa isoform of myosin heavy chain can be phosphorylated in cultured smooth muscle cells59 as well as in vitro with specific protein kinases. pump is stimulated by agents that increase cGMP, such as atrial natriuretic factor and nitrovasodilators. 90 The specific mechanism may involve generation of phosphatidylinositol diphosphate, which has been shown to increase pump activity. 90 The Na+-H+ exchanger of vascular smooth muscle has received considerable attention because its activity is modulated by contractile agonists and mitogens.91 Cellular alkalinization is an early but not necessarily obligatory event in the steps leading to vascular myocyte proliferation.91 Inhibitors of the Na+-H+ exchanger, such as amiloride, possess antimitogenic activity.91 By extruding H' and importing Na+, Na+-H+ exchange can indirectly increase intracellular levels of Ca`. The latter occurs via exchange of the increased intracellular Na4 for Ca`+.92 Ca> entering the cell by means of the Na+-Ca2+ exchanger is available for contraction or cellular growth and proliferation. Recently, a cDNA encoding the human amiloride-sensitive Na+-H+ exchanger has been cloned and sequenced. 93 The availability of this information should facilitate investigation of several problems, including the existence of tissue-specific isoforms, the molecular mechanisms of regulation, and the identification of protein domains responsible for ion and/or drug inhibitor binding.
Unlike skeletal muscle but similar to cardiac muscle, vascular myocytes are coupled via intercellular pathways of low electrical resistance.5 This process is mediated by connexons, or gap junctions, that are composed of a hexameric array of a 43,000-Da protein.94 A eDNA encoding the vascular gap junctional protein has been cloned and sequenced. 95 The deduced amino acid sequence shows virtual identity with the cardiac connexon-43. Moreover, both cultured vascular cells of the modulated phenotype and vascular endothelial cells express RNA for connexon-43.95 Thus, intercellular coupling in cardiac and vascular tissues appears to be mediated by gap junctions of similar protein composition. Although incompletely studied, vascular gap junctions are likely to play an important role in coordinating the contraction of blood vessel segments.
Signal Transduction
Receptors for a-and ,3-adrenergic, muscarinic cholinergic, serotonin, and peptide hormones such as angiotensin are coupled to intracellular second-messenger systems through membrane-bound guanine nucleotide binding (G) proteins.96 The G-proteins consist of three subunits (a, /3, and y) with the a-subunit conferring specificity.96 For example, the ,82-adrenergic receptor is coupled to adenylate cyclase via G., where s is stimulatory. Many of the G-proteins and the genes encoding them have been identified through DNA-cloning techniques.97 In addition, cDNAs encoding the adrenergic and muscarinic cholinergic have been cloned and sequenced. 98 On the other hand, few studies have been undertaken to thoroughly characterize molecular diversity of receptor subtypes and G-proteins in vascular PKcpathway is also activated by growth factors such asplatelet-derived growth factors (PDGF). PDGF binds to a specific receptor (PDGF-R), which is also a tyrosine kinase, that transfers phosphate from ATP to various proteins (tyrosine-P). Two other mechanisms for Ca2' entry into the cytoplasm include Na+-Ca2' exchange (Na+-Ca2' exch.) and release of Ca21 from SR via specialized Ca2+-release channels, also known as ryanodine receptors (Ry) because of their capacity to bind this plant alkaloid. Na+-Ca21 exchange occurs in response to increases in intracellular Na+, whereas Ca2' release via Ry is stimulated by Ca2+. 
